udden cardiac death (SCD) accounts for approximately one-third of all deaths in patients with heart failure. 1 It is primarily caused by ventricular tachycardia (VT) and/or ventricular fibrillation (VF): an analysis of 157 documented cases of SCD showed that 83% were caused by VT progressing to VF, or to primary VF. 2 Therefore, prevention of VT/VF is a key issue in the treatment of heart failure patients.
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There are mutual interactions between heart failure and arrhythmia; heart failure predisposes to arrhythmia and arrhythmias aggravate heart failure. In addition, certain therapies for heart failure are undesirable for arrhythmia, and certain therapies for arrhythmia can exacerbate heart failure.
Mechanisms of VT/VF in Heart Failure

Ventricular Remodeling and Arrhythmogenic Substrates
Development and progression of heart failure is associated with structural and functional remodeling of the ventricles, including spatially heterogeneous fibrosis, hypertrophy, necrosis, ischemia, apoptosis, and disruption of intercellular communication via the cell membrane and the gap junction. These changes result in depolarization abnormalities and repolarization dispersion of cardiomyocytes.
The action potential duration (APD) in ventricular muscle has been shown to be prolonged in failing hearts through a decrease of outward currents and/or an increase of inward currents. As to the changes in outward currents, reductions in the Ca 2+ -independent transient outward current (Ito), inward rectifier K + current (IK1) and delayed rectifier K + currents (IKr, IKs) have been reported. 3, 4 For the inward currents, the Na + /Ca 2+ exchange current (INa/Ca) is increased, 5 whereas the L-type Ca 2+ current (ICa,L) is unaffected. 6 Upregulation of the hyperpolarization-activated inward current (If) 7 and an increase of the stretch-activated nonselective cation channel current (ISAC) 8 have been also reported.
Gap junction remodeling in the failing heart, in concert with interstitial fibrosis, may produce substrates for reentrant arrhythmias through the creation of a spatially heterogeneous conduction disturbance. Downregulation of connexin (Cx) 43, an altered phosphorylation state of Cx43, and upregulation of Cx40 and Cx45 have been reported. 9 Altered Ca 2+ handling in the ventricular myocytes plays an important role in the development of ventricular tachyarrhythmias in the failing heart. A reduction of Ca 2+ uptake into the sarcoplasmic reticulum (causing intracellular Ca 2+ overload), an increase in spontaneous Ca 2+ leakage from the sarcoplasmic reticulum Ca 2+ -release channels (ryanodine receptors), and an increase in INa/Ca have been recognized in animal models of heart failure, and in part in human patients with extensive heart failure. 10 A combination of these events sets the stage for triggered activities resulting from oscillation of membrane potentials characterized by early afterdepolarization or delayed afterdepolarization. Activation of If or ISAC may contribute to enhanced automaticity (Fig 1) .
in heart failure facilitates myocardial fibrosis causing arrhythmogenic substrates. 10 A meta-analysis of large-scale clinical studies found that angiotensin-converting enzyme inhibitors (ACEIs) reduced the incidence of SCD in postmyocardial infarction patients. 13 Myocardial ischemia, acidosis, free radicals, and extracellular electrolyte abnormalities (eg, hyperkalemia, hypokalemia, and hypomagnesemia) are involved in the onset of arrhythmia (Fig 1) .
Drug therapy for heart failure (eg, diuretics, ACEIs, and aldosterone antagonists) can be arrhythmogenic through modification of the renin -angiotensin system and by electrolyte imbalances. Clinical studies of phosphodiesterase inhibitors done in the 1990s showed that inotropic agents in heart failure resulted in increased mortality despite certain improvements in the patients' cardiac function, exercise tolerance, and symptoms. 14 
Drug Therapy to Terminate VT/VF
Immediate defibrillation by DC shocks is mandatory for the treatment of VT/VF associated with serious hemodynamic deterioration. Defibrillation by DC shocks is usually carried out with 200 J of biphasic or 360 J of monophasic pulses, and if this is ineffective the shocks are repeated after intravenously injecting epinephrine or vasopressin. 15 The main emphasis is on life-saving, rather than on treating the arrhythmia; the primary therapeutic focus is on maintaining organ blood flow. If the arrhythmia persists after several DC shocks, lidocaine, procainamide, amiodarone, or nifekalant is given intravenously. A placebo-controlled, randomized, comparative study (ARREST study) examined intravenous amiodarone in patients with VF or pulseless VT who had an out-of-hospital cardiac arrest and did not respond to at least 3 DC shocks. The ratio of successful resuscitation was significantly higher in patients treated with amiodarone than in those treated with placebo (44% and 34%, respectively, p=0.03). 16 The 'Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation' (ALIVE) study compared the efficacy of intravenous injection of amiodarone and lidocaine in patients who had out-of-hospital VF that was resistant to DC shocks, including those unresponsive to defibrillation following intravenous injection of epinephrine. The ratio of successful resuscitation was significantly higher in patients treated with amiodarone than in those treated with lidocaine (22.8% and 12.0%, respectively, p=0.009). 17 Several nonrandomized clinical studies in Japan have suggested the usefulness of nifekalant for resuscitating patients who develop out-ofhospital cardiopulmonary arrest resistant to DC shocks. [18] [19] [20] A post-marketing study of nifekalant documented that 13 of 26 patients with VF (50%) were successfully defibrillated by nifekalant alone and 15 of 30 patients who had VF resistant to DC shocks were successfully defibrillated by repeat DC shock following intravenous injection of nifekalant. 21 In sustained VT with stable hemodynamics, either intravenous lidocaine or nifekalant is indicated. Although intravenous procainamide is indicated for mild heart failure, its use can exacerbate heart failure, as well as leading to hypotension and prolonged QRS. 22 
Drug Therapy to Prevent VT/VF
Beta-Blockers
In heart failure patients, the level of norepinephrine in the myocardium is elevated, and there are ion current abnormalities. At the cardiomyocyte level, stimulation ofadrenergic receptors alters the activity of a number of ion channels and transporters. 10 In the nonfailing human heart, approximately 80% of adrenergic receptors are 1-receptors and 20% are 2-receptors. Stimulation of these receptors leads to activation of adenylyl cyclase and formation of cyclic AMP through the activated stimulatory G-protein (Gs). In the failing human heart, however, there is selective downregulation of 1-receptors and relative upregulation of 2-receptors to approximately 40%. 23 , 24 The 2-receptors not only link to the Gs, but also to inhibitory G-protein (Gi), which hypothetically may ameliorate the harm of excessive adrenergic stimulation.
Beta-blockers have multiple antiarrhythmic mechanisms, and should be particularly effective in arrhythmia caused by increased sympathetic drive in heart failure. They also suppress structural remodeling of the heart induced by sympathetic stimulation through modification of cell growth, apoptosis and extracellular matrix composition. 12 Metoprolol is a selective 1-adrenergic antagonist; it changes action potentials and alters membrane currents by suppressing various ion channels. An experimental study showed that metoprolol shortened the APD and inhibited IK1, ICa, and Ito Mechanisms of arrhythmia in heart failure. Heart failure leads to structural and electrical remodeling that can initiate and sustain fatal ventricular arrhythmia by reentrant mechanisms (altered repolarization, increased dispersion of refractoriness, and delayed conduction), with enhanced triggered activity and automaticity, or both. Modifiers, including neurohormonal stimulation, myocardial ischemia and stress, act on these mechanisms to produce an unstable milieu. RyR2, ryanodine receptor 2; SR, sarcoplasmic reticulum; EAD, early afterdepolarization; DAD, delayed afterdepolarization.
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in isolated feline ventricular myocytes. 25 Carvedilol blocks not only 1-but also 2-and 1-adrenergic receptors. In addition, carvedilol has an antioxidant effect. In experiments on rabbit ventricular myocytes, carvedilol was shown to have direct inhibitory effects on a variety of ionic currents, especially on IKr, Ito, ICa,L and, to a lesser extent, IKs. The APD of ventricular muscle is prolonged moderately by carvedilol through a reduction of IKr, but the QT interval on ECG is virtually unaffected, probably because of a concomitant reduction of ICa,L. [26] [27] [28] Table 1 summarizes the large-scale clinical studies onblockers in heart failure patients. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study, carvedilol showed a 76% reduction in the incidence of malignant ventricular arrhythmia (VT, VF or ventricular flutter) compared with placebo in post-myocardial infarction patients with low cardiac function (left ventricular ejection fraction (LVEF) ≤40%). 39 The Carvedilol Or Metoprolol European Trial (COMET), in which carvedilol and metoprolol were randomly assigned to heart failure patients, has shown that carvedilol-treated patients experienced a 20% greater reduction in cardiovascular death and a 19% greater reduction in SCD than the metoprolol-treated patients. 37, 38 In COMET, however, there was no significant difference in outcome or survival between the 2 groups based on target dose achieved. 40 The potential advantage of carvedilol over metoprolol in the treatment of heart failure patients might be related to their different pharmacological properties. Beta1-receptors in the failing heart are upregulated by metoprolol, but are unaffected by carvedilol. 41 Carvedilol, unlike metoprolol, is known to have a vasodilatory action through 1 blockade, as well as antioxidant effects.
ACEIs/Angiotensin Receptor Blockers (ARBs)
A meta-analysis of large-scale clinical studies indicated that ACEIs lowered the incidence of SCD in post-myocardial infarction patients, 13 and that they may partially affect the onset of arrhythmia in heart failure. The VasodilatorHeart Failure Trial II (V-HeFT-II) compared enalapril and hydralazine combined with isosorbide in chronic heart failure patients with LVEF <45%, and found that enalapril slightly reduced the incidence of SCD. 42 The Cooperative North Scandinavian Enalapril Survival Trial (CONSEN-SUS) 43 and Studies of Left Ventricular Dysfunction (SOLVD) 44 in severe heart failure patients showed that enalapril reduced total mortality, but had no significant affect on SCD. ARBs are expected to have similar beneficial effects to ACEIs on the survival of heart failure patients, most likely through prevention of ventricular structural remodeling. However, large-scale clinical trials will be required to substantiate this speculation.
Aldosterone Antagonists
In the Randomized Aldactone Evaluation Study (RALES), severe heart failure patients with LVEF ≤35% and NYHA functional class III/IV were randomly assigned to receive spironolactone (an aldosterone antagonist) or standard agents, such as ACEIs and loop diuretics. The results showed that spironolactone significantly reduced total mortality (relative mortality risk 0.70, p<0.001) and SCD (relative mortality risk 0.71, p=0.02). 45 In the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study (EPHESUS) involving acute myocardial infarction patients, eplerenone (an aldosterone antagonist) significantly lowered total mortality (relative mortality risk 0.85, p=0.008) and SCD (relative mortality risk 0.79, p=0.03). 46 The exact mechanisms of the reduction of mortality by aldosterone antagonists remain to be elucidated.
Amiodarone
Amiodarone affects a variety of inward and outward ion channel currents, suppresses sympathetic activities, and modifies thyroid function. Like lidocaine, it blocks the Na + channel current (INa) through a high affinity for the inactivated state and relatively fast binding/unbinding kinetics. Amiodarone blocks both voltage-gated and ligand-gated K + channel currents; the former include IKr and Ito, and the latter, acetylcholine-sensitive K + currents (IK,ACh) and ATPsensitive K + currents (IK,ATP). The pharmacological actions of amiodarone can be divided into acute and chronic. The major acute electrophysiological effect of amiodarone on the heart is a moderate suppression of excitability and conductivity through blockade of ICa,L and INa. The major chronic electrophysiological effect is a moderate prolongation of APD by reducing IK (especially IKs) and Ito. 47 The Cardiac Arrhythmia Suppression Trial (CAST) revealed that treatment of ventricular arrhythmia with potent INa blockers (Class I antiarrhythmic drugs) in postmyocardial infarction patients results in increased mortality and SCD. 48 Subsequently, many clinical trials to evaluate the potential benefit of Class III antiarrhythmic drugs and amiodarone for the prevention of SCD have been conducted. A meta-analysis of 13 randomized trials showed that amiodarone significantly reduced overall mortality by 13%, and arrhythmic mortality and SCD by 29%. 49 Two large-scale randomized trials have assessed amiodarone as a primary prevention for SCD in heart failure patients. The Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (CHF-STAT) in heart failure patients (>10 premature ventricular beats per hour and LVEF ≤40%) found no reduction in overall mortality and no SCD benefit from amiodarone, although there was a trend toward reduced overall mortality among patients with nonischemic cardiomyopathy (p=0.07) (Fig 2) . 50 In contrast, the use of amiodarone in the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial in patients with severe heart failure because of nonischemic (70%) or ischemic (30%) cardiomyopathy showed a 28% risk reduction in mortality, both SCD and heart failure death, independently of the presence of nonsustained VT (Fig 3) . 51 Although ICDs have been shown in several trials to be superior in preventing SCD among high-risk patients, 52 the Amiodarone Versus Implantable Cardioverter-Defibrillator: Kaplan-Meier estimates of overall mortality in ischemic or nonischemic cardiomyopathy from the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (CHF-STAT) in 674 patients with congestive heart failure. Note that amiodarone had no significant effect on mortality as compared with placebo among patients with ischemic heart failure, but there was a trend in favor of amiodarone over placebo among those with a nonischemic cause (Reproduced from N Engl J Med 1995; 333: 77 -82 with permission). Kaplan-Meier estimates of sudden cardiac death (A) or death because of progressive heart failure (B) from the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial in 516 patients with severe heart failure caused by nonischemic (70%) or ischemic (30%) cardiomyopathy. Note the reduction in sudden cardiac death and heart failure death in the amiodarone group as compared with the control group (Reproduced from Lancet 1994; 344: 493 -498 with permission).
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Randomized Trial (AMIOVIRT) in nonischemic dilated cardiomyopathy patients with LVEF ≤35% and nonsustained VT found no reduction in overall mortality benefit from ICD treatment (Fig 4) . 53 In recent years, -blocker therapy has been established as a treatment option for heart failure. The Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) and European Myocardial Infarct Amiodarone Trial (EMIAT) in myocardial infarction patients with reduced LVEF showed that the interaction of amiodarone with a -blocker was significant for preventing cardiac death (p=0.05) and arrhythmic death or resuscitated cardiac arrest (p=0.03). 54 The Optimal Pharmacology Therapy in Cardioverter Defibrillator Patients (OPTIC) study also demonstrated a favorable interaction of amiodarone andblocker. 55 Therefore, amiodarone may be useful as an adjunctive therapy in at least some heart failure patients, together with ACEIs, -blockers and an ICD, and is potentially effective for preventing VT/VF, especially in highrisk patients with nonischemic heart failure.
Sotalol
Sotalol is a unique -blocker that possesses substantial Class III activity. It is a racemic compound, but the Class II activity arises only from l-sotalol, although both isomers have Class III activity. The Electrophysiological Study Versus Electrocardiographic Monitoring (ESVEM) trial showed that sotalol was better than 6 Class I antiarrhythmic drugs in patients with sustained VT/VF, although the study was not designed to compare the efficacy of antiarrhythmics. 56 However, the pure Class III agent d-sotalol increased mortality in post-myocardial infarction patients with LVEF ≤40% in the Survival With ORal D-sotalol (SWORD) study. 57 Therefore, racemic sotalol (d,l-sotalol) is used clinically.
Sotalol can exacerbate heart failure in patients with low LVEF because of its negative inotropic effect. The -blocking activity, but not the Class III activity, of sotalol is evident at low dosages. 58 Sotalol has a different spectrum of adverse effects from amiodarone, and is less likely to cause extracardiac reactions. But, because sotalol prolongs the APD, it can cause torsades de pointes (TdP) accompanied with QT prolongation.
Pure Class III Agents
Since the CAST study, attention has shifted to Class III antiarrhythmic drugs, such as amiodarone, and pure Class III agents have been developed as new potential antiarrhythmics. However, most of the newly developed pure Class III agents have been discontinued because of undesirable side-effects, especially Tdp with QT prolongation.
In Japan, the pure Class III agent, intravenous nifekalant, was approved for the treatment of the following types of lethal VT/VF: (1) recurrent sustained VT/VF with organic heart disease resistant to Class I agents, (2) incessant VT induced by Class I agents; (3) sustained VT where amiodarone is of limited value; and (4) VF resistant to DC shocks. Nifekalant is also useful in heart failure patients because of its positive inotropic effect. In Japan, postmarketing studies have shown that nifekalant prevented VT/VF recurrence in 60 of 99 patients (60.6%) in the emergency setting, and tended to improve the hemodynamic state after maintenance infusion. 21 Nifekalant exerts its effect mainly by inhibition of IKr. It is likely to induce marked QT prolongation and Tdp by bradycardia because of its reverse use-dependent effect Therefore, it is important to closely monitor QT time, heart rate, and electrolytes, particularly the serum K level.
Conclusions
Preventing VT/VF resulting in SCD is a critical issue in the treatment of heart failure patients. Although ICDs reduce SCD, they are limited to preventing triggers for VT/VF or cardiac death in heart failure patients. Antiarrhythmic drugs with Class III activity have an important role in the treatment of ventricular tachyarrhythmia with heart failure. Optimal drug therapy, including -blockers,
